Companies › Vertex Pharmaceuticals
17 active drug programs in 38 registered trials: 19 Phase 3, 9 Phase 1, 5 Phase 2, 5 Phase 4; Respiratory, Neurology, Genitourinary, Metabolic and endocrine; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Suzetrigine (SUZ, VX-548) Nav1.9 sodium channel inhibitor | Ion channels | Phase 4 | Pain; Diabetic Peripheral Neuropathic Pain; Opioid Consumption, Postoperative; Bariatric Surgery … | Jan 2027 |
| Ivacaftor Cystic fibrosis transmembrane conductance regulator positive modulator; Cystic fibrosis transmembrane conductance regulator activator | CFTR | Phase 3 | Cystic Fibrosis; Cystic Fibrosis (CF) | Apr 2027 |
| Tezacaftor Cystic fibrosis transmembrane conductance regulator positive modulator | CFTR | Phase 3 | Cystic Fibrosis; Cystic Fibrosis (CF) | Apr 2027 |
| Exagamglogene Autotemcel (CTX001) B-cell lymphoma/leukemia 11A gene editing negative modulator | BCL11A | Phase 3 | Sickle Cell Disease; Beta-Thalassemia | Jun 2027 |
| VX-880 (Zimislecel, formerly STx-02) Engineered insulin-producing cells derived from human pluripotent stem cells | – | Phase 3 | Type 1 Diabetes; Diabetes Mellitus, Type 1 | Sep 2027 |
| VX-017 Immune modulatory cell therapy | – | Phase 3 | Diabetes Mellitus, Type 1 | Dec 2027 |
| VX-121/TEZ/D-IVA CFTR modulator combination: VX-121 (CFTR potentiator) + tezacaftor (CFTR corrector) + deut | CFTR | Phase 3 | Cystic Fibrosis | – |
| VX-407 PKD1 gene variant-targeted therapy | – | Phase 2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Dec 2026 |
| VX-993 Selective sodium channel inhibitor | – | Phase 2 | Diabetic Peripheral Neuropathic Pain | Mar 2027 |
| VX-147 APOL1 inhibitor | APOL1 | Phase 2 | Proteinuric Kidney Disease | Jun 2028 |
| Povetacicept | – | Phase 2 | Primary Membranous Nephropathy; Myasthenia Gravis, Generalized | Dec 2028 |
| VX-670 | – | Phase 1 | Myotonic Dystrophy Type 1 (DM1) | Feb 2027 |
| VX-433 | – | Phase 1 | Narcolepsy Type 1 (NT1) | Mar 2027 |
| VX-264 Allogeneic human stem cell-derived islets | – | Phase 1 | Type 1 Diabetes | Mar 2027 |
| VX-272 | – | Phase 1 | Cystic Fibrosis | Jun 2027 |
| VX-581 CFTR modulator (specific mechanism not stated) | – | Phase 1 | Cystic Fibrosis | Jul 2027 |
| VX-522 mRNA therapy encoding CFTR | CFTR | Phase 1 | Cystic Fibrosis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05668741 | VX-522 | Phase 1 | Cystic Fibrosis | Respiratory | Apr 2026 |
| NCT07813039 | VX-581 | Phase 1 | Cystic Fibrosis | Respiratory | Oct 2026 |
| NCT05444257 | VX-121/TEZ/D-IVA | Phase 3 | Cystic Fibrosis | Respiratory | Oct 2026 |
| NCT07868926 | VX-407 | Phase 1 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Genitourinary | Dec 2026 |
| NCT07539623 | Suzetrigine (SUZ, VX-548) | Phase 3 | Bariatric Surgery | Cardiovascular | Dec 2026 |
| NCT06696443 | Suzetrigine (SUZ, VX-548) | Phase 3 | Diabetic Peripheral Neuropathic Pain | Neurology | Jan 2027 |
| NCT07538570 | Suzetrigine (SUZ, VX-548) | Phase 4 | Pain | Other | Jan 2027 |
| NCT06185764 | VX-670 | Phase 1 | Myotonic Dystrophy Type 1 (DM1) | Neurology | Feb 2027 |
| NCT07548385 | Suzetrigine (SUZ, VX-548) | Phase 3 | Total Knee Replacement Surgery | Other | Feb 2027 |
| NCT07584434 | VX-433 | Phase 1 | Narcolepsy Type 1 (NT1) | Neurology | Mar 2027 |
| NCT07792408 | VX-407 | Phase 1 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Genitourinary | Mar 2027 |
| NCT05791201 | VX-264 | Phase 1 | Type 1 Diabetes | Metabolic and endocrine | Mar 2027 |
| NCT06619860 | VX-993 | Phase 2 | Diabetic Peripheral Neuropathic Pain | Neurology | Mar 2027 |
| NCT05331183 | Tezacaftor | Phase 3 | Cystic Fibrosis | Respiratory | Apr 2027 |
| NCT07231419 | Suzetrigine (SUZ, VX-548) | Phase 3 | Diabetic Peripheral Neuropathic Pain | Neurology | Apr 2027 |
| NCT05331183 | Ivacaftor | Phase 3 | Cystic Fibrosis | Respiratory | Apr 2027 |
| NCT06628908 | Suzetrigine (SUZ, VX-548) | Phase 3 | Diabetic Peripheral Neuropathic Pain | Neurology | May 2027 |
| NCT05329649 | Exagamglogene Autotemcel (CTX001) | Phase 3 | Sickle Cell Disease | Hematology | Jun 2027 |
| NCT05477563 | Exagamglogene Autotemcel (CTX001) | Phase 3 | Beta-Thalassemia | Hematology | Jun 2027 |
| NCT07672015 | Suzetrigine (SUZ, VX-548) | Phase 4 | Opioid Consumption, Postoperative | Other | Jun 2027 |
| NCT07437105 | VX-272 | Phase 1 | Cystic Fibrosis | Respiratory | Jun 2027 |
| NCT07283770 | VX-581 | Phase 1 | Cystic Fibrosis | Respiratory | Jul 2027 |
| NCT07525219 | Suzetrigine (SUZ, VX-548) | Phase 3 | Analgesic Efficacy | Other | Jul 2027 |
| NCT07161037 | VX-407 | Phase 2 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Genitourinary | Jul 2027 |
| NCT06832410 | VX-880 (Zimislecel, formerly STx-02) | Phase 3 | Type 1 Diabetes | Metabolic and endocrine | Sep 2027 |
| NCT06460506 | Tezacaftor | Phase 3 | Cystic Fibrosis | Respiratory | Sep 2027 |
| NCT07226700 | Suzetrigine (SUZ, VX-548) | Phase 3 | Total Hip Arthroplasty (THA) | Other | Nov 2027 |
| NCT05356195 | Exagamglogene Autotemcel (CTX001) | Phase 3 | Beta-Thalassemia | Hematology | Nov 2027 |
| NCT04786262 | VX-017 | Phase 3 | Diabetes Mellitus, Type 1 | Metabolic and endocrine | Dec 2027 |
| NCT04786262 | VX-880 (Zimislecel, formerly STx-02) | Phase 3 | Diabetes Mellitus, Type 1 | Metabolic and endocrine | Dec 2027 |
| NCT07809867 | Tezacaftor | Phase 4 | Cystic Fibrosis (CF) | Respiratory | Apr 2028 |
| NCT05312879 | VX-147 | Phase 2 | Proteinuric Kidney Disease | Genitourinary | Jun 2028 |
| NCT07204275 | Povetacicept | Phase 2 | Primary Membranous Nephropathy | Genitourinary | Dec 2028 |
| NCT07864896 | Suzetrigine (SUZ, VX-548) | Phase 3 | Total Knee Arthroplasty (TKA) | Other | Jan 2029 |
| NCT07501702 | Povetacicept | Phase 2 | Myasthenia Gravis, Generalized | Neurology | Mar 2029 |
| NCT04602468 | Tezacaftor | Phase 4 | Cystic Fibrosis | Gastroenterology | Jul 2029 |
| NCT05422222 | Tezacaftor | Phase 3 | Cystic Fibrosis | Respiratory | Jun 2030 |
| NCT07148739 | Ivacaftor | Phase 4 | Cystic Fibrosis (CF) | Respiratory | Dec 2030 |
Cash of $218m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Valenta Pharm JSC Biogen Alnylam Pharmaceuticals Chiesi Farmaceutici Ionis Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.